Spotlight Interview: Sharon Kleefield, Ph.D., Healthcare Standards Institute

About Sharon Kleefield, Ph.D. Retired faculty, Harvard Medical School (HMS), and former Director of Healthcare Quality at Harvard Medical International. Her work has focused on developing and deploying standards in healthcare. Her expertise includes Health Care Management Education and Training programs for clinical staff both at HMS and globally. Prior to

Industry News: Volume 2, Issue 3

Echosens Presents Research at 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan Mitigates Risk of Patients Developing Fibrosis/Cirrhosis PARIS & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan® family of products, is pleased to announce its strong presence at the upcoming American Association for the Study of Liver Diseases

Volume 2, Issue 2: Christine Cooper, CEO, and Jack Towarnicky, ERISA Counsel, aequum, LLC Discuss Protecting Plan Participants with Self-Funded Health Plans from Surprise and Balance Billings

Dear Colleagues, Good news for the medical travel community, domestic and international: Medical Travel & Digital Health News (MTDHN) has been accepted as the sponsor of the first “Medical Travel Month” – January 2022 – in the Society for Healthcare Marketing and Development, American Hospital Association’s “2022 Calendar of Health Observances

Industry News: Volume 2, Issue 2

Medicare Punishes 2,499 Hospitals for High Readmissions By Jordan Rau KHN.com—The federal government’s effort to penalize hospitals for excessive patient readmissions is ending its first decade with Medicare cutting payments to nearly half the nation’s hospitals. In its 10th annual round of penalties, Medicare is reducing its payments to 2,499 hospitals, or 47%

Volume 2, Issue 1: Frank Amato, President and CEO, and Dr. Daniel Alkon, Chief Scientific Advisor, SYNAPS Dx, Discuss First Minimally Invasive Test for Alzheimer’s Disease

Dear Colleagues, Good news for the medical travel community, domestic and international: Medical Travel & Digital Health News (MTDHN) has been accepted as the sponsor of the first “Medical Travel Month” – January 2022 – in the Society for Healthcare Marketing and Development, American Hospital Association’s “2022 Calendar of Health Observances

Spotlight Interview: Frank Amato, President and CEO, SYNAPS Dx, and Dr. Daniel Alkon, Chief Scientific Advisor, SYNAPS Dx

About Frank Amato Frank Amato is CEO and president of SYNAPS Dx. Previously, after two decades in the pharmaceutical and biotech industries, he was president, CEO and director of electroCore, a NASDAQ-traded bioelectronic medicine company focused on treating neurodegenerative conditions. Frank is an accomplished leader with a track record for consistently

Industry News: Volume 2, Issue 1

SYNAPS Dx Completes $10 Million Series A Investment, Accelerates Commercialization of DISCERN: First Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), announces the close

Volume 1, Issue 23: National Breast Cancer Awareness Month: Liz Cormier-May, CEO, Mammogen, Inc. Discusses Digital Diagnostics for the Early Detection of Breast Cancer in Women

Dear Colleagues, Good news for the medical travel community, domestic and international: Medical Travel & Digital Health News (MTDHN) has been accepted as the sponsor of the first “Medical Travel Month” – January 2022 – in the Society for Healthcare Marketing and Development, American Hospital Association’s “2022 Calendar of Health Observances

Spotlight Interview: Liz Cormier-May, CEO, Mammogen, Inc.

About Elizabeth Cormier-May Liz has been in the biotechnology industry for nearly 20 years, with a focus on early start-ups and company creation.  She started her career as a medicinal chemist for Novartis Institute for Biomedical Research, working in early discovery oncology.  She quickly realized that her ability to create meaningful